About
HeartFlow is an FDA-cleared, AI-driven cardiac analysis platform designed to transform how clinicians diagnose and manage coronary artery disease (CAD). Its flagship product, the Heartflow One platform, takes a standard coronary CT angiography (CCTA) scan and converts it into a detailed, interactive 3D model of the patient's heart — providing unprecedented visibility into both the anatomy and physiology of the coronary vasculature. The platform consists of three core analytical modules: Roadmap™ Analysis, which enables fast, consistent CCTA reading for early CAD detection; FFR CT Analysis, which non-invasively assesses blood flow across the coronary tree to determine whether revascularization is needed; and Plaque Analysis, which quantifies and characterizes coronary plaque to guide long-term risk management. Conventional diagnostic methods such as stress EKGs, PET scans, and calcium scoring carry significant rates of false negatives (20–30%) and false positives (55%), leading to missed diagnoses or unnecessary interventional procedures. HeartFlow addresses these shortcomings by providing precise, patient-specific data that supports confident clinical decision-making. Supported by over 600 peer-reviewed publications and endorsed by scientific statements from the American College of Cardiology and American Heart Association, HeartFlow is the most clinically validated AI framework for coronary risk stratification. The platform also includes comprehensive clinical, operational, technical, and financial support services for institutions building scalable CCTA programs. HeartFlow is designed for cardiologists, interventional cardiologists, and cardiac imaging specialists at hospitals and health systems seeking to personalize patient care and improve outcomes in CAD management.
Key Features
- Roadmap™ Analysis: Enables fast, consistent reading of every CCTA scan for accurate and early detection of coronary artery disease across all readers.
- FFR CT Analysis: Non-invasively assesses blood flow throughout the entire coronary tree to determine whether revascularization procedures are warranted.
- Plaque Analysis: Quantifies and characterizes coronary plaque burden to inform patient risk stratification and guide long-term disease management strategies.
- Personalized 3D Heart Modeling: Converts standard CCTA scans into dynamic, patient-specific 3D heart models that reveal both anatomical structure and physiological function.
- Heartflow One Platform Support: Provides clinical, operational, technical, and financial resources to help institutions build and scale efficient CCTA diagnostic programs.
Use Cases
- Early and accurate detection of coronary artery disease using AI-enhanced CCTA analysis to reduce missed diagnoses.
- Personalized treatment planning for cardiac patients by combining anatomical and blood flow data into individualized care pathways.
- Pre-procedural planning for interventional cardiologists performing percutaneous coronary intervention (PCI) using the PCI Navigator tool.
- Long-term coronary plaque monitoring and risk stratification to guide preventive cardiology and medication management.
- Building and scaling hospital CCTA programs with clinical, technical, and financial support from the HeartFlow One platform.
Pros
- Clinically Validated: Backed by 600+ peer-reviewed publications and endorsed by the American College of Cardiology and American Heart Association, making it the most validated AI framework for coronary risk stratification.
- Reduces Diagnostic Errors: Dramatically cuts down on the false positives (55%) and false negatives (20–30%) associated with conventional diagnostic methods like stress EKG and PET scans.
- Comprehensive, End-to-End Platform: Covers the full CAD management lifecycle — from identification and decision support to long-term plaque monitoring — within a single integrated platform.
- Broad Insurance Coverage: Covered by 99.5% of US lives, reducing financial barriers for healthcare institutions and patients seeking CCTA-based diagnosis.
Cons
- Requires CCTA Infrastructure: Institutions must already have or invest in coronary CT angiography capabilities to leverage the HeartFlow platform, which may be a barrier for smaller facilities.
- Enterprise-Only Pricing: HeartFlow is an enterprise medical product with no publicly available pricing, making cost evaluation opaque for institutions exploring adoption.
- Not Consumer-Facing: The platform is designed exclusively for healthcare professionals and institutions, with no direct access or tools available for patients or general users.
Frequently Asked Questions
What is HeartFlow and how does it work?
HeartFlow is an AI-powered medical imaging platform that takes a coronary CT angiography (CCTA) scan and transforms it into a personalized 3D model of the patient's heart. This model provides both anatomical and physiological insights, enabling cardiologists to accurately detect and manage coronary artery disease.
What is FFR CT Analysis?
FFR CT Analysis is HeartFlow's non-invasive tool that uses computational fluid dynamics to simulate blood flow through the coronary arteries, helping physicians determine whether specific blockages are causing reduced blood flow and whether an interventional procedure like stenting is needed.
Who is HeartFlow designed for?
HeartFlow is designed for cardiologists, interventional cardiologists, cardiac CT specialists, and healthcare institutions such as hospitals and health systems that diagnose and manage coronary artery disease.
Is HeartFlow covered by insurance?
Yes — HeartFlow is covered by 99.5% of US lives, making it accessible through most major insurance plans for patients undergoing CCTA-based cardiac evaluations.
What is Plaque Analysis and why does it matter?
Plaque Analysis is HeartFlow's module for quantifying and characterizing coronary plaque in CCTA scans. It helps clinicians assess a patient's cardiovascular risk, personalize medical therapy, and monitor disease progression over time, supporting long-term CAD management rather than one-time diagnosis.
